We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
(-30%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
266.32%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
Baxter International
BAX
|
+$3.81M |
| 3 |
Akebia Therapeutics
AKBA
|
+$2.87M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.46M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$8.82M |
| 2 |
CELG
Celgene Corp
CELG
|
+$6.57M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$6.35M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$5.44M |
| 5 |
Viatris
VTRS
|
+$2.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.43% |
| 2 | Technology | 4.06% |
| 3 | Consumer Discretionary | 2.5% |
| 4 | Consumer Staples | 1.74% |
| 5 | Materials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
Walmart Inc
WMT
$909B
| $226K | 0.24% |
+285,000
| New | +$6.25M |
|
|
YHOO
77
CALL
DELISTED
Yahoo Inc
YHOO
| $223K | 0.23% |
39,200
+29,200
| +292% | +$915K |
|
78
SCYNEXIS
SCYX
$42.4M
| $222K | 0.23% |
689
+216
| +46% | +$81.8K |
|
|
MDVN
79
CALL
DELISTED
MEDIVATION, INC.
MDVN
| $221K | 0.23% |
+50,100
| New | +$1.82M |
|
|
80
CALL
Gilead Sciences
GILD
$167B
| $218K | 0.23% |
82,100
+57,100
| +228% | +$5.15M |
|
81
Starbucks
SBUX
$120B
| $214K | 0.22% |
+3,581
| New | +$209K |
|
|
82
PUT
Chipotle Mexican Grill
CMG
$44.2B
| $211K | 0.22% |
225,000
-815,000
| -78% | -$7.75M |
|
|
NBRV
83
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $208K | 0.22% |
+93
| New | +$200K |
|
84
CALL
Edwards Lifesciences
EW
$49.4B
| $207K | 0.22% |
+157,500
| New | +$4.35M |
|
85
PUT
Humana
HUM
$48B
| $202K | 0.21% |
9,400
| – | – |
|
|
86
CALL
Humana
HUM
$48B
| $198K | 0.21% |
19,000
+18,000
| +1,800% | +$3.12M |
|
87
CALL
Apple
AAPL
$4.9T
| $196K | 0.21% |
+111,600
| New | +$2.78M |
|
|
YHOO
88
DELISTED
Yahoo Inc
YHOO
| $193K | 0.2% |
5,241
-28,500
| -84% | -$893K |
|
89
CALL
Adobe
ADBE
$94.3B
| $188K | 0.2% |
+10,000
| New | +$867K |
|
90
PUT
Monster Beverage
MNST
$95.4B
| $186K | 0.19% |
169,800
+43,800
| +35% | +$976K |
|
|
THS
91
CALL
DELISTED
Treehouse Foods
THS
| $178K | 0.19% |
+17,100
| New | +$1.37M |
|
|
TYC
92
CALL
DELISTED
TYCO INTL PLC COM SHS (IRL)
TYC
| $178K | 0.19% |
+98,365
| New | +$3.51M |
|
|
FPRX
93
PUT
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $174K | 0.18% |
34,300
+2,000
| +6% | +$68.7K |
|
|
TWC
94
CALL
DELISTED
TIME WARNER CABLE INC NEW COM STK
TWC
| $172K | 0.18% |
+12,400
| New | +$2.34M |
|
|
SVVC
95
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
| $167K | 0.17% |
+22,238
| New | +$161K |
|
|
CEMP
96
DELISTED
Cempra, Inc.
CEMP
| $165K | 0.17% |
9,400
-40,272
| -81% | -$730K |
|
97
PUT
lululemon athletica
LULU
$13.2B
| $156K | 0.16% |
+20,000
| New | +$1.2M |
|
98
PUT
Radware
RDWR
$1.27B
| $156K | 0.16% |
+25,000
| New | +$302K |
|
99
PUT
Broadcom
AVGO
$1.76T
| $154K | 0.16% |
54,980
-4,020
| -7% | -$54.3K |
|
100
CALL
Cigna
CI
$74.5B
| $153K | 0.16% |
+22,600
| New | +$3.1M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2016 Portfolio in Review
As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.
- FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
- FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
- FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
- FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
- FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
- FT Options opened 183 new positions and closed 99 in Q1 2016.
- FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.
Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.